

Monica Balzarotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415315/publications.pdf>

Version: 2024-02-01

102
papers

4,454
citations

159585

30
h-index

106344

65
g-index

105
all docs

105
docs citations

105
times ranked

4003
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FILDLCL04 trial. <i>British Journal of Haematology</i> , 2022, 196, 1184-1193.	2.5	19
2	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
3	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.	7.2	56
4	A brief rituximab, bendamustine, mitoxantrone (R ² BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	2.5	4
5	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	4.6	29
6	A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Investigational New Drugs</i> , 2021, 39, 1028-1035.	2.6	4
7	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	1.6	74
8	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. <i>Annals of Hematology</i> , 2021, 100, 2547-2556.	1.8	1
9	Risk-tailored treatment of splenic marginal zone lymphoma. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	1.4	0
10	CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL). <i>Frontiers in Oncology</i> , 2021, 11, 730194.	2.8	0
11	Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?. <i>Annals of Translational Medicine</i> , 2020, 8, 1035-1035.	1.7	5
12	Small lymphocytic lymphoma in true trilineage hematopoietic tissue within heterotopic ossification in an enucleated blind painful eye: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 92.	0.8	1
13	Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number. <i>Blood</i> , 2020, 136, 38-39.	1.4	1
14	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020, 136, 16-17.	1.4	2
15	Erratum to checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?. <i>Annals of Translational Medicine</i> , 2020, 8, 1474-1474.	1.7	0
16	Efficacy and Feasibility of DA-EPOCH-R in Aggressive B-Cell Lymphoma: A Real Life Single-Center Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S250.	0.4	0
17	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167.	1.7	15
18	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	3.7	10

#	ARTICLE	IF	CITATIONS
19	MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). <i>HemaSphere</i> , 2019, 3, e305.	2.7	4
20	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 398-398.	1.4	10
21	Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome. <i>Blood</i> , 2019, 134, 4116-4116.	1.4	2
22	The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 2025-2025.	1.4	0
23	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.	1.7	34
24	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1530-1542.	10.7	91
25	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , the, 2017, 4, e510-e523.	4.6	258
26	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	10.7	100
27	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.8	31
28	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 TF	0.9	20
29	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e217-e227.	4.6	442
30	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	1.3	7
31	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. <i>Blood</i> , 2016, 128, 511-511.	1.4	13
32	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3049-3049.	1.4	2
33	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015, 100, e423-e427.	3.5	7
34	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015, 90, 56-61.	4.1	3
35	High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. <i>Bone Marrow Transplantation</i> , 2015, 50, 499-504.	2.4	9
36	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIMâ€PET</sc>) of standard therapy on treatment outcome in early stage <sc>H</sc>odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	4.1	49

#	ARTICLE	IF	CITATIONS
37	Autologous Stem Cell Transplantation Followed By Allogeneic SCT Provides Promising Results in Patients with Relapsed DLBCL and Adverse Prognostic Features Compared with ASCT Alone. <i>Blood</i> , 2015, 126, 2034-2034.	1.4	0
38	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	1.2	67
39	MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.	1.1	38
40	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	1.6	149
41	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. <i>Bone Marrow Transplantation</i> , 2014, 49, 1475-1480.	2.4	41
42	Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8530-8530.	1.6	0
43	Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 3863-3863.	1.4	0
44	Diagnosis and Treatment of Hodgkin's Lymphoma. , 2013, , 985-1013.		0
45	Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2013, 48, 249-252.	2.4	15
46	Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The "Rete Ematologica Lombarda/Hematology Network Of Lombardia Region". <i>Blood</i> , 2013, 122, 3003-3003.	1.4	1
47	Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 5088-5088.	1.4	0
48	Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2012, 17, 838-846.	3.7	114
49	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012, 97, 416-422.	3.5	61
50	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. <i>Haematologica</i> , 2012, 97, 1073-1079.	3.5	108
51	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1013-1022.	1.8	36
52	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Blood</i> , 2012, 120, 1566-1566.	1.4	2
53	Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).. <i>Blood</i> , 2012, 120, 2720-2720.	1.4	1
54	R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2012, 120, 1615-1615.	1.4	0

#	ARTICLE	IF	CITATIONS
55	What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study "Refol" by the Fondazione Italiana Linfomi (FIL) On 548 Patients. <i>Blood</i> , 2012, 120, 154-154.	1.4	0
56	Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ®) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970). <i>Blood</i> , 2012, 120, 3644-3644.	1.4	0
57	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	1.6	190
58	Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience. <i>Leukemia Research</i> , 2011, 35, 712-714.	0.8	14
59	Positron Emission Tomography Status and Tandem High-Dose Therapy Favorably Influence Outcome of Patients with Relapsed and/or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 335-335.	1.4	0
60	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma (FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011, 118, 2636-2636.	1.4	0
61	Autologous Transplantation Followed by Reduced-Intensity Allogeneic Transplantation Is Feasible in Patients with High-Risk Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 3105-3105.	1.4	0
62	IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease. <i>Blood</i> , 2010, 116, 3890-3890.	1.4	4
63	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. <i>Blood</i> , 2010, 116, 966-966.	1.4	3
64	Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2010, 116, 1761-1761.	1.4	7
65	Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. <i>British Journal of Haematology</i> , 2009, 145, 369-372.	2.5	51
66	Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 432-438.	2.0	26
67	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009, 374, 1512-1520.	13.7	588
68	Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 35-41.	3.5	216
69	High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2444-2446.	1.3	0
70	Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study. <i>American Journal of Hematology</i> , 2007, 82, 122-127.	4.1	27
71	ICEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. <i>Bone Marrow Transplantation</i> , 2007, 40, 1019-1025.	2.4	20
72	CD34 dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. <i>European Journal of Haematology</i> , 2007, 78, 111-116.	2.2	6

#	ARTICLE	IF	CITATIONS
73	Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. <i>European Journal of Haematology</i> , 2007, 78, 322-329.	2.2	24
74	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2006, 17, 533.	1.2	3
75	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.1	83
76	Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.. <i>Blood</i> , 2006, 108, 208-208.	1.4	5
77	Comprehensive Geriatric Assessment-Adapted Chemotherapy in 100 Elderly Patients (>70 Years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 2440-2440.	1.4	1
78	What is the Best Option to Cure Patients with Resistant/Relapsing Hodgkins Disease?. <i>Current Stem Cell Research and Therapy</i> , 2006, 1, 419-424.	1.3	4
79	Primary mediastinal B-cell lymphoma with sclerosis: Report of 11 cases treated with intensified-CHOP plus radiotherapy. <i>American Journal of Hematology</i> , 2005, 78, 312-313.	4.1	4
80	Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin's Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.. <i>Blood</i> , 2005, 106, 2091-2091.	1.4	7
81	Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen. <i>Bone Marrow Transplantation</i> , 2004, 33, 1067-1068.	2.4	5
82	Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: Survey from a single institution. <i>American Journal of Hematology</i> , 2003, 73, 267-272.	4.1	17
83	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 20-27.	1.6	420
84	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1439-1440.	1.3	8
85	Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true?. <i>Annals of Oncology</i> , 2003, 14, 1155-1156.	1.2	0
86	Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour. <i>British Journal of Cancer</i> , 2003, 89, 1159-1161.	6.4	29
87	Comprehensive Geriatric Evaluation in Elderly Patients With Lymphoma: Feasibility of a Patient-Tailored Treatment Plan. <i>Journal of Clinical Oncology</i> , 2003, 21, 754-754.	1.6	27
88	High-Dose Chemotherapy in Poor-Prognosis Adult Small Round-Cell Tumors: Clinical and Molecular Results From a Prospective Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 2181-2188.	1.6	71
89	Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. <i>Annals of Oncology</i> , 2002, 13, 1341-1346.	1.2	24
90	Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. <i>Bone Marrow Transplantation</i> , 2002, 30, 207-214.	2.4	9

#	ARTICLE	IF	CITATIONS
91	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002, 87, 1258-64.	3.5	141
92	Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2001, 28, 923-927.	2.4	20
93	Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study. <i>Annals of Oncology</i> , 2000, 11, 231-233.	1.2	32
94	Dose-escalation of CHOP in non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1999, 10, 519-526.	1.2	28
95	PCR-based clonality analysis: a reliable method for the diagnosis and follow-up monitoring of conservatively treated gastric B-cell MALT lymphomas?. <i>Histopathology</i> , 1999, 34, 326-330.	2.9	34
96	Intensified CHOP in non-Hodgkin's lymphoma: What we know and what we need to know. <i>Annals of Oncology</i> , 1999, 10, 875-876.	1.2	3
97	Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. <i>British Journal of Cancer</i> , 1998, 77, 992-997.	6.4	27
98	Initial chemotherapy for primary resectable large-cell lymphoma of the stomach. <i>Annals of Oncology</i> , 1997, 8, 497-499.	1.2	36
99	Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.. <i>Journal of Clinical Oncology</i> , 1997, 15, 528-534.	1.6	171
100	Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996, 7, 970-972.	1.2	20
101	Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: The Milan Cancer Institute Experience. <i>Annals of Oncology</i> , 1993, 4, 831-837.	1.2	58
102	Study of the HLA-DP β 1 Locus by the Polymerase Chain Reaction Technique in Patients with Hodgkin's Disease. <i>Tumori</i> , 1993, 79, 133-136.	1.1	2